Android Apple

Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

By Yahoo! Finance   |   4 months ago
Longeveron® Presents Study Results from CLEAR MIND Phase 2a Clinical Trial of Lomecel-B™ in Mild Alzheimer's Disease at the Alzheimer's Association International Conference® (AAIC)

Longeveron Inc. presents promising Phase 2a clinical trial data on Lomecel-B™ at the AAIC 2024, showing improvements in cognitive function and brain volume in mild Alzheimer's Disease. The therapy demonstrated safety and efficacy, supporting its potential as a novel treatment.

Read More

Did you find this insightful?

close

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.